The DOI matches its Crossref record; 44 of the 44 references it cites were found in a registry or an index.
Bilateral visual improvement with unilateral gene therapy injection for Leber hereditary optic neuropathy
Open accessAbstract
At 96 weeks after unilateral intravitreal injection of rAAV2/2- ND4 , vision improved in both eyes in 78% of subjects affected with LHON.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Among RESCUE subjects, BCVA evolution was comparable in both rAAV2/2-ND4etreated and shamtreated eyes, similar to the bilateral changes seen among subjects in the REVERSE study.18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“A total of 78% of patients experienced some bilateral improvement of BCVA from baseline; 81% experienced a CRR from nadir in at least 1 eye, and 76% had an improvement of at least À0.3 logMAR (15 ETDRS letters equivalent) from nadir in at least 1 eye.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“It is also the first clinical study assessing the efficacy of a bilateral IVT of lenadogene nolparvovec, while in the three previous clinical studies REVEAL,21 REVERSE16–18 and RESCUE,17–19 lenadogene nolparvovec was exclusively administered as unilateral IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The REVERSE (NCT02652780), RESCUE (NCT02652767), and REFLECT (NCT03293524) Phase III studies in LHON all reported a similar inci dence of intraocular inflammation with the same construct and dose of AAV vector despite different prophylaxis regimes.”
From Gene Therapy-Associated Uveitis (GTAU): Understanding and mitigating the adverse immune response in retinal gene therapy (2025) · cites this paper as Yu-Wai-Man et al., 2020
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the REVERSE trial, LHON subjects had loss of vision in both eyes of 6 months to 1 year at study enrollment, and a bilateral visual improvement was observed over the 96 weeks after treatment administration.18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“RESCUE and REVERSE 18 are not the only studies to report bilateral BCVA improvement after unilateral injection of gene therapy.”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the REVERSE study, at week 96, rAAV2/2-ND4etreated eyes showed a LS mean improvement from baseline in BCVA of À0.308 logMAR (þ15 ETDRS letters equivalent), and sham-treated eyes showed an LS mean improvement from baseline of À0.259 logMAR (þ13 ETDRS letters equivalent).18”
From Efficacy and Safety of Intravitreal Gene Therapy for Leber Hereditary Optic Neuropathy Treated within 6 Months of Disease Onset (2021) · cites this paper as [18]
The cited source says what the claim attributes to it.
In the citing paper
“This study suggested there is some transfer of viral vector DNA from the injected eyes to the uninjected contralateral eyes after unilateral lenadogene IVT.”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
The cited source says what the claim attributes to it.
In the citing paper
“The absence of systemic issues related to lenadogene nolparvovec treatment is supported by the limited biodissemination of the product, which is negligible in the blood of REFLECT patients, similar to what has been observed in previous clinical studies.16,19”
From Randomized trial of bilateral gene therapy injection for m.11778G>A MT-ND4 Leber optic neuropathy (2023) · cites this paper as [16]
In the citing paper
“RESCUE and REVERSE (ClinicalTrial.gov NCT02652767 and NCT026527080) (15,16) were 2 randomized, double-masked, sham-controlled, multicenter, international, pivotal clinical trials to evaluate the efficacy of a single IVT of rAAV2/2-ND4 in subjects with LHON secondary to the m.11778G>A mutation.”
From Cross-sectional analysis of baseline visual parameters in subjects recruited into the RESCUE and REVERSE ND4-LHON gene therapy studies (2021) · cites this paper as [16]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
(2005) · American Journal of Ophthalmology · doi:10.1016/j.ajo.2005.03.057 · Cited by 4,396
Russell, S., Bennett, J., Wellman, J. A., Chung, D. C., Yu, Z.-F., Tillman, A., Wittes, J., Pappas, J., Elci, O., McCague, S., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31868-8 · Cited by 1,952
Proper Method for Calculating Average Visual Acuity
Holladay, J. T. (1997) · Journal of Refractive Surgery · doi:10.3928/1081-597x-19970701-16 · Cited by 1,097
Zingg, B., Chou, X.-L., Zhang, Z., Mesik, L., Liang, F., Tao, H. W., & Zhang, L. I. (2016) · Neuron · doi:10.1016/j.neuron.2016.11.045 · Cited by 775
Standardizatlon of Vitreal inflammatory Activity in Intermediate and Posterior Uveitis
Nussenblatt, R. B., Palestine, A. G., Chan, C.-C., & Roberge, F. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34001-0 · Cited by 684
A randomized placebo-controlled trial of idebenone in Leber’s hereditary optic neuropathy.
Klopstock, T., Yu-Wai-Man, P., Dimitriadis, K., Rouleau, J., Heck, S., Bailie, M., Atawan, A., Chattopadhyay, S., Schubert, M., Garip, A., et al. (2011) · Brain · doi:10.1093/brain/awr170 · Cited by 578
Self-citationSingle-cell analysis of experience-dependent transcriptomic states in the mouse visual cortex
Hrvatin, S., Hochbaum, D. R., Nagy, M. A., Cicconet, M., Robertson, K., Cheadle, L., Zilionis, R., Ratner, A., Borges-Monroy, R., Klein, A. M., et al. (2018) · Nature Neuroscience · doi:10.1038/s41593-017-0029-5 · Cited by 497
The Epidemiology of Leber Hereditary Optic Neuropathy in the North East of England
Yu‐Wai‐Man, P., Griffiths, P. G., Brown, D. T., Howell, N., Turnbull, D. M., & Chinnery, P. F. (2003) · The American Journal of Human Genetics · doi:10.1086/346066 · Cited by 485
Self-citationNewman, N. J., Lott, M. T., & Wallace, D. C. (1991) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(14)76784-4 · Cited by 403
Self-citationGiordano, C., Iommarini, L., Giordano, L., Maresca, A., Pisano, A., Valentino, M. L., Caporali, L., Liguori, R., Deceglie, S., Roberti, M., et al. (2013) · Brain · doi:10.1093/brain/awt343 · Cited by 282
Self-citation
Flagged first, then by citations
Cited by
Sorted by citations
Items 201–232 of 232
Hassan, A. K., & Serhan, H. A. A. (2025) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_2898_23
Animal Models in Neuro Ophthalmology
Normando, E. M., Sher, A., Patel, R. P., Arora, N., & Cordeiro, M. F. (2025) · Springer eBooks · doi:10.1007/978-3-031-72156-4_19
Hereditäre Optikusneuropathien
Rüther, K. (2025) · Springer Reference Medizin · doi:10.1007/978-3-662-65823-9_75
Sherratt‐Mayhew, S., Page, C., Berman, G., & Mollan, S. P. (2025) · Eye · doi:10.1038/s41433-025-03932-w
(2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00033-7
Neuhofer, C. M., Gasser, T., & Klopstock, T. (2022) · Elsevier eBooks · doi:10.1016/b978-3-437-21884-2.00027-1
Self-citationShah, V. S., Coussa, R. G., & Traboulsi, E. I. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0043
Emerging Instruments for Measuring Patient-Reported Outcomes in Inherited Retinal Diseases
Maiz, A. M., Abuzaitoun, R., & Jayasundera, T. (2025) · Oxford University Press eBooks · doi:10.1093/med/9780197659403.003.0059
Harvey, J. P., Hong, E. H., & Yu‐Wai‐Man, P. (2025) · Clinical and Experimental Ophthalmology · doi:10.1111/ceo.14583
Self-citationChen, B. S., Seikus, C., Ferguson, J., Tadić, V., Horton, M., Yu‐Wai‐Man, P., & Archer, S. (2025) · Value in Health · doi:10.1016/j.jval.2025.07.023
Self-citationWang, H., Shi, T., Wang, W., Li, J., Chen, Z., Lan, L., Xie, L., Xiong, F., Wang, D., Guan, J., et al. (2025) · Orphanet Journal of Rare Diseases · doi:10.1186/s13023-025-04040-4
Development of Two In Vitro ND1 -LHON Models for Evaluating Gene Therapy Efficacy
Li, X., Yuan, J. J., Chen, Z., Zhang, Y., Liu, Y., & Zhang, Y. (2025) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.66.13.34
Leber Hereditary Optic Neuropathy: Ocular Genetics
Uçak, T., & Saygın, I. Ö. (2025) · Güncel Retina Dergisi (Current Retina Journal) · doi:10.37783/crj-0535
Rufa, A., Plantone, D., Bargagli, A., Righi, D., Bacci, T., Serchi, V., Primiano, G., Gallus, G. N., Lopergolo, D., Pretegiani, E., et al. (2025) · Brain Communications · doi:10.1093/braincomms/fcaf446
Gene Therapy for Leber Hereditary Optic Neuropathy (LHON): A Systematic Review and Meta-Analysis
Alghamdi, L. N., Alsudais, A. S., Almarwani, S. H., Alraddadi, R. A., Alsamadani, A. H., Alnamlah, A. A., Aljehani, S., Allarakia, Y. F., Alghamdi, A. M., & Alshowaeir, D. (2026) · Neuro-Ophthalmology · doi:10.1080/01658107.2026.2624440
Oxidative stress imbalance and cellular damage mediated by the ND4 G11778A mutation
Fang, L., Fu, K., Yang, M., Xu, Y., Ukamaka, E. S., Qu, D., Huang, T., & Hu, J. (2026) · Scientific Reports · doi:10.1038/s41598-026-40061-0
Evaluation of a Child With Optic Atrophy
Koester, K. H., & Ditta, L. C. (2026) · International Ophthalmology Clinics · doi:10.1097/iio.0000000000000608
Rôle de SLC6A14 dans la physiopathologie pulmonaire de la mucoviscidose
Mercier, J. (2021) · theses.fr (ABES) · doi:10.70675/6e115649zd82ez404azba02zb48dd44c464f
Khanna, R. K., Cui, X., Wong, D., Makam, R., Ducloyer, J., de la Barca, J. M. C., Bocca, C., Vignal‐Clermont, C., Blasco, H., Orssaud, C., et al. (2026) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2026.04.006
Self-citationEmerging therapeutic strategies for mitochondrial DNA-related diseases
Shi, R., Falabella, M., Aref, J., Hanna, M. G., Minczuk, M. A., Viscomi, C. F., & Pitceathly, R. D. S. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.102841
Abu‐Amero, K. K. (2026) · International Journal of Molecular Sciences · doi:10.3390/ijms27146128
Bunnell, B., López, F. J., Yuan, D., Robinson, M. R., Duncan, J. L., & Birch, D. G. (2026) · Ophthalmology Science · doi:10.1016/j.xops.2026.101323
Ambika, S., & Sundaramurthy, S. (2026) · Indian Journal of Ophthalmology · doi:10.4103/ijo.ijo_1696_25
Leber’s hereditary optic nerve atrophy
Оренбуркина, О. И., Frolov, M. A., Babushkin, A. E., Vorobyeva, I. V., Фролов, М. А., & Koshelev, D. I. (2026) · Russian Annals of Ophthalmology · doi:10.17116/oftalma2026142041105
El-Dairi, M., & Estrela, T. (2026) · Elsevier eBooks · doi:10.1016/b978-0-323-93040-6.00111-7
Gene therapy clinical trials for inherited eye diseases: The pediatric perspective
Sandali, A., Nikolaidou, A., Gianni, T., Tsoukala, Z., Tsinopoulos, I., & Lamprogiannis, L. P. (2026) · European Journal of Ophthalmology · doi:10.1177/11206721261478166
Omics in optic neuropathies: From molecular landscapes to personalized therapeutics
Wu, S., Tan, K., Qiu, M., Chen, Y., Li, J., Hu, Y., & Zhou, H. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101526
Progress in gene therapy for RPGR-associated X-linked retinitis pigmentosa
Elsayed, M. E. A. A., & MacLaren, R. E. (2026) · Expert Opinion on Biological Therapy · doi:10.1080/14712598.2026.2733200
Hedström, J., Nilsson, M., Fagerström, S., Engvall, M., Williams, P. A., & Venkataraman, A. P. (2026) · Eye · doi:10.1038/s41433-026-04866-7
Mastering the eye: Clinical paradigm shifts from optical restoration to genomic correction
Zhang, X., Li, F., Huang, D., Yu‐Wai‐Man, P., Grzybowski, A. E., Aung, T., Lam, D. S. C., & Weinreb, R. N. (2026) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2026.101537
Self-citationKrawczynski, M. R., Everdingen, J. V., Leroy, B. P., Verny, C., Bauer, N. J. C., Andris, C., Lorenz, B., Votruba, M., Priglinger, C., Jurkutė, N., et al. (2026) · Journal of Neurology · doi:10.1007/s00415-026-14181-6
Self-citationOvens, C. A., Grigg, J., & Fraser, C. L. (2026) · Research Square · doi:10.21203/rs.3.rs-11028896/v1
Metadata
- Authors
- Yu-Wai-Man, P., Newman, N. J., Carelli, V., Moster, M. L., Biousse, V., Sadun, A. A., Klopstock, T., Vignal-Clermont, C., Sergott, R. C., Rudolph, G., La Morgia, C., Karanjia, R., Taiel, M., Blouin, L., Burguière, P., Smits, G., Chevalier, C., Masonson, H., Salermo, Y., Katz, B., Picaud, S., Calkins, D. J., & Sahel, J.-A.
- Affiliations
- Cambridge Centre for Brain Repair and MRC Mitochondrial Biology Unit, Department of Clinical Neurosciences, University of Cambridge, Cambridge CB2 0PY, UK.
- Emory University (US)
- IRCCS Istituto delle Scienze Neurologiche di Bologna, UOC Clinica Neurologica, 40139 Bologna, Italy.
- Thomas Jefferson University (US)
- Departments of Ophthalmology, Neurology and Neurological Surgery, Emory University School of Medicine, Atlanta, GA 30322, USA.
- University of California, Los Angeles (US)
- German Center for Neurodegenerative Diseases (DE)
- Department of Neuro-Ophthalmology and Emergencies, Rothschild Foundation Hospital, 75019 Paris, France.
- LMU Klinikum (DE)
- University of Ottawa (CA)
- GenSight Biologics (France) (FR)
- GenSight Biologics, New York, NY 10016, USA.
- Centre National de la Recherche Scientifique (FR)
- Vanderbilt University Medical Center (US)
- Corresponding author
- Sahel, José-Alain
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2020-12-09
- Volume
- 12
- Issue
- 573
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- OpenAlex
- W3112356895
- Semantic Scholar
- 2da05deb776c7a779083c86633384a37dd820660
- Cited by
- 232
- References
- 44
- Citations by year
- 2026: 23 · 2025: 39 · 2024: 34 · 2023: 39 · 2022: 42 · 2021: 49 · 2020: 5
- FWCI
- 10.95
- Type
- journal article
- Language
- en
- Open access
- Licence
- other-oa
- Locations
- Science Translational Medicine (publishedVersion)
- PubMed (publishedVersion)
- HAL (submittedVersion, other-oa)
- Archivio istituzionale della ricerca (Alma Mater Studiorum Università di Bologna) (submittedVersion, cc-by-nd)
- DZNE Pub (submittedVersion)
- Apollo (University of Cambridge) (submittedVersion)
- Apollo
- Funders
- GenSight Biologics
- Topics
- Health Sciences › Medicine › Ophthalmology › Retinal Development and Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Virus-based gene therapy research
- Health Sciences › Medicine › Ophthalmology › Glaucoma and retinal disorders
- Keywords
- Leber's hereditary optic neuropathy, gene therapy, unilateral injection, nonhuman primate model, visual recovery, optic nerve, retina, anterior segment
- MeSH terms
- Dependovirus, Animals, Humans, NADH Dehydrogenase, Visual Acuity, Visual Fields, Genetic Therapy, Optic Atrophy, Hereditary, Leber, Tomography, Optical Coherence
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
